Sorafenib Tosylate — CAS 475207-59-1

Sorafenib Tosylate is the tosylate salt form of Sorafenib, a multikinase inhibitor with enhanced bioavailability used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. Mediocon Inc manufactures GMP-compliant Sorafenib Tosylate API at its Aurangabad facility.

• Hepatocellular carcinoma (HCC)
• Renal cell carcinoma (RCC)
• Thyroid cancer treatment
• Angiogenesis inhibition

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / EP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support